Skip to main content

Animations

MJFF Publications

801 - 810 of 6516 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2021
  • 2020
  • 2021
  • 2020
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Symposia
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/ene.15461
    Citation Count: 3
  • Summary Details
    OPEN
    Title: An efficient and scalable synthesis of thiazolo ring fused 2-pyridones using flow chemistry
    Journal Name: Arkivoc
    Publisher: ARKAT USA, Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.24820/ark.5550190.p011.445
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
    Journal Name: Journal of Managed Care & Specialty Pharmacy
    Publisher: Academy of Managed Care Pharmacy
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.18553/jmcp.2021.27.6.785
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
    Journal Name: Molecular Cancer Therapeutics
    Publisher: American Association for Cancer Research (AACR)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1158/1535-7163.mct-20-0259
    Citation Count: 14
  • Summary Details
    OPEN
    Title: CD4 + T cells contribute to neurodegeneration in Lewy body dementia
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.abf7266
    Citation Count: 215
  • Summary Details
    OPEN
    Title: Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.aaw0843
    Citation Count: 90
  • Summary Details
    OPEN
    Title: Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides
    Journal Name: ACS Chemical Biology
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acschembio.1c00487
    Citation Count: 37
  • Summary Details
    OPEN
    Title: PARIS farnesylation prevents neurodegeneration in models of Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.aax8891
    Citation Count: 63
  • Summary Details
    OPEN
    Title: Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration
    Journal Name: Science Signaling
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scisignal.abg3555
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.0c00801
    Citation Count: 52
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.